Patents by Inventor Robert A. Lazarus

Robert A. Lazarus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20190177366
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, JR., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE
    Publication number: 20190078160
    Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
    Type: Application
    Filed: April 20, 2018
    Publication date: March 14, 2019
    Applicant: Genentech, Inc.
    Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Loyet, Henry R. Maun, Brian L. Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y. Hernandez-Barry
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20190054138
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • Method of reducing blood glucose by administering RON agonists
    Patent number: 10005848
    Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: June 26, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jackson G Egen, Jo-Anne Hongo, Steven Kauder, Robert A Lazarus, Lydia Santell, Yan Wu, Meredith Hazen, Wei-Ching Liang
  • Nucleic acid molecules encoding for BACE1 antibodies
    Patent number: 9879094
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • CHAGASIN-BASED SCAFFOLD COMPOSITIONS, METHODS, AND USES
    Publication number: 20170174733
    Abstract: Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).
    Type: Application
    Filed: June 19, 2015
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Robert A. LAZARUS, Henry R. MAUN
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20170106042
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: May 23, 2016
    Publication date: April 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • Peptide inhibitors of BACE1
    Patent number: 9624269
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 18, 2017
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • METHODS AND COMPOSITIONS FOR NEURAL DISEASE IMMUNOTHERAPY
    Publication number: 20170058049
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: August 11, 2016
    Publication date: March 2, 2017
    Applicant: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • PEPTIDE INHIBITORS OF BACE1
    Publication number: 20160304563
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Application
    Filed: November 20, 2015
    Publication date: October 20, 2016
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • Methods and compositions for neural disease immunotherapy
    Patent number: 9453079
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 27, 2016
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Method for generating potent dendritic cells
    Patent number: 9273284
    Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: March 1, 2016
    Assignee: The Regents of the University of California
    Inventors: Robert Lazarus Modlin, Mirjam Schenk
  • RON COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160032013
    Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.
    Type: Application
    Filed: May 29, 2015
    Publication date: February 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: JACKSON G. EGEN, JO-ANNE HONGO, STEVEN KAUDER, ROBERT A. LAZARUS, LYDIA SANTELL, YAN WU, MEREDITH HAZEN, WEI-CHING LIANG
  • Peptide inhibitors of BACE1
    Patent number: 9193766
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: November 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20150126448
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: June 26, 2014
    Publication date: May 7, 2015
    Applicant: GENENTECH, INC.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • METHODS AND COMPOSITIONS FOR NEURAL DISEASE IMMUNOTHERAPY
    Publication number: 20140286963
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 25, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • PEPTIDE INHIBITORS OF BACE1
    Publication number: 20140228277
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: August 14, 2014
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • BACE1 antibodies
    Patent number: 8772457
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Method for Generating Potent Dendritic Cells
    Publication number: 20140056845
    Abstract: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.
    Type: Application
    Filed: April 16, 2012
    Publication date: February 27, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robert Lazarus Modlin, Mirjam Schenk
  • Zymogen activators
    Patent number: 8623821
    Abstract: Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 7, 2014
    Assignee: Genentech, Inc.
    Inventors: Kyle E. Landgraf, Robert A. Lazarus